The likelihood for avoidance of five clinically important outcomes in patients with COPD and type 2 inflammation was greater ...

Dupilumab and omalizumab are both effective adjuvant treatments for adults with bullous pemphigoid, though dupilumab may provide better outcomes.

Children with asthma experienced fewer exacerbations and better control with dupilumab regardless of the duration of their disease, according to a poster at the American Thoracic Society International ...

A new study published in the Journal of the European Academy of Dermatology and Venerology found dupilumab to have a ...

All participants will initially undergo a run-in period on standardised medium-dose ICS/LABA to confirm persistent lack of ...

today announced 24 abstracts on Dupixent ® (dupilumab) clinical data and real-world analyses in respiratory diseases will be presented at the American Thoracic Society (ATS) International ...

Sanjay Ramakrishnan, MD, senior lecturer, University of Western Australia, discusses the value of the win ratio approach in ...

Discover a study that highlights a potentially critical role for the BDNF-NTRK2 pathway in EoE symptom development.

Mepolizumab has had a bumpy road to arriving at its indication in COPD. An FDA advisory committee in 2018 declined to ...

The University of Virginia Medical Center is not just one of Newsweek’s top 50 hospitals in the country (and No. 1 in the ...

The poster presentations will be available on Connect’s website under the Presentations and Publications section.

The FDA granted Priority Review to lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP). Lenacapavir is a long-acting HIV-1 capsid inhibitor administered as a twice-yearly ...